By posting a big gain Friday after pricing an upsized IPO at the top end of its range, ORIC provided another encouraging data point to biotechs seeking to test the public markets, suggesting that investors...

A day after Arch and Flagship unveiled dueling billion dollar funds, venBio is staying the course with a more modest $394 million fund. What is new for the nine-year-old firm is a dramatic shift away...

With a $55 million series D round and recent hires from Ignyta and Genentech, ORIC believes it has the money and the team to advance multiple drug-resistant cancer therapies through clinical studies. ORIC Pharmaceuticals Inc....

Strategic LPs once again dominate the second fund from venBio LLC, even though none of the first fund's M&A exits went to an LP. The firm's Global Strategic Fund II closed last week at $315...

The Column Group plans to invest its biggest fund yet in fewer companies. The goal is to infuse enough capital into platform-based newcos that they can turn a blind eye to the capital markets. At...

The Column Group closed its third fund at $535 million, founder and Managing Partner Peter Svennilson disclosed to BioCentury. He said the firm intends to invest the new fund in about eight companies. TCG closed...

The team and investors behind drug-resistant cancer companies Aragon Pharmaceuticals Inc. and Seragon Pharmaceuticals Inc. are back for thirds with Oric Pharmaceuticals Inc. , which hopes to take a broader approach than its predecessors by focusing...

Oric Pharmaceuticals Inc. (South San Francisco, Calif.) raised $53 million in a series B round with The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Foresite Capital and Kravis Investment Partners. Oric's unnamed lead compound...

While many VCs have deemed chronic diseases such as diabetes a no-fly zone because of clinical development costs, investors in Metacrine Inc .'s $36 million series A round are taking a contrarian approach. The expectation...

GTx Inc. thinks there are lessons about castration-resistant prostate cancer to be learned from breast cancer. The company has licensed a technology from the University of Tennessee Research Foundation that selectively degrades androgen receptors, and...